Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Genomics' New Resolution

This article was originally published in Start Up

Executive Summary

In distancing itself from developing technology for single-molecule genome sequencing, US Genomics has partly moved from developing a potentially disruptive technology to providing incremental improvements, first in genomics research. The appeal is that the start-up can get to the market and generate product revenues faster. But whether its new focus will provide the big margins or access to big markets that venture investors find appealing remains an open question.

You may also be interested in...



Instrumental Improvement: Solexa Merges With Lynx

Reverse merging into Lynx gives high-throughput sequencing play Solexa the instrument development capabilities, Nasdaq listing and US presence it lacked. What's more, combining Solexa's sequencing technology with the commercial infrastructure at Lynx was enough to secure top-notch management and cash to see the company through to its first product offering, expected as early as late 2005.

Instrumental Improvement: Solexa Merges With Lynx

Reverse merging into Lynx gives high-throughput sequencing play Solexa the instrument development capabilities, Nasdaq listing and US presence it lacked. What's more, combining Solexa's sequencing technology with the commercial infrastructure at Lynx was enough to secure top-notch management and cash to see the company through to its first product offering, expected as early as late 2005.

Making a New, Big Splash in the Sequencing Market

If one of the first ingredients of a successful tool company deal is to invest as little capital as possible, what then to make of the hefty $27 million raised by Helicos, a developer of high-throughput sequencing systems? The company that successfully integrates the technologies needed for single-molecule sequencing could find a fast and rewarding exit, and neither their investors nor management reject the possibility of a buy-out even before their products hit the market in a few years.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel